Since Cambrex Corporation (NYSE:CBM) and Benitec Biopharma Limited (NASDAQ:BNTC) are part of the Biotechnology industry, they are influenced by contrast. The influences particularly affect the risk, analyst recommendations, profitability, dividends, institutional ownership, earnings and valuation of both companies.
Valuation & Earnings
|Gross Revenue||Price/Sales Ratio||Net Income||Earnings Per Share||Price/Earnings Ratio|
|Benitec Biopharma Limited||N/A||0.00||N/A||-0.82||0.00|
Table 1 demonstrates Cambrex Corporation and Benitec Biopharma Limited’s gross revenue, earnings per share (EPS) and valuation.
Table 2 represents Cambrex Corporation (NYSE:CBM) and Benitec Biopharma Limited (NASDAQ:BNTC)’s return on assets, net margins and return on equity.
|Net Margins||Return on Equity||Return on Assets|
|Benitec Biopharma Limited||0.00%||0%||0%|
Cambrex Corporation and Benitec Biopharma Limited Ratings and Recommendations are available on the next table.
|Sell Ratings||Hold Ratings||Buy Ratings||Rating Score|
|Benitec Biopharma Limited||0||0||0||0.00|
Cambrex Corporation has a consensus price target of $49, and a 11.64% upside potential.
Institutional & Insider Ownership
Roughly 0% of Cambrex Corporation shares are owned by institutional investors while 4.11% of Benitec Biopharma Limited are owned by institutional investors. Insiders owned roughly 0.7% of Cambrex Corporation’s shares.
In this table we provide the Weekly, Monthly, Quarterly, Half Yearly, Yearly and YTD Performance of both pretenders.
|Performance (W)||Performance (M)||Performance (Q)||Performance (HY)||Performance (Y)||Performance (YTD)|
|Benitec Biopharma Limited||32.73%||44.42%||-9.25%||-22.06%||-33.96%||46%|
For the past year Cambrex Corporation has weaker performance than Benitec Biopharma Limited
Cambrex Corporation beats on 10 of the 11 factors Benitec Biopharma Limited.
Cambrex Corporation, a life sciences company, provides various products and services for the development and commercialization of new and generic therapeutics worldwide. The companyÂ’s products comprise active pharmaceutical ingredients and pharmaceutical intermediates that are used in the production of prescription and over-the-counter drug products, as well as other fine chemicals. It serves generic drug companies; and companies that discover and commercialize small molecule human therapeutics. The company sells its products directly, as well as through independent agents. Cambrex Corporation was founded in 1981 and is headquartered in East Rutherford, New Jersey.
Benitec Biopharma Limited, a biotechnology company, develops treatments for chronic and life-threatening human diseases based on its gene silencing therapy, DNA-directed RNA interference (ddRNAi) in Australia and the United States. The company provides BB-301, a single administration ddRNAi-based gene therapy for the treatment of oculopharyngeal muscular dystrophy; BB-201, a ddRNAi-based therapy for the treatment of wet age-related macular degeneration; and BB-101 and BB-103 ddRNAi-based therapies for the treatment of human hepatitis B. It also offers BB-401 and BB-501 for the treatment of oncology. The company was founded in 1995 and is headquartered in North Sydney, Australia.